| LDR | | 08349cmm u2200733 i 4500 |
| 001 | | 000000327847 |
| 003 | | OCoLC |
| 005 | | 20240307140716 |
| 006 | | m d |
| 007 | | cr un||||||||| |
| 008 | | 230802s2023 dcu o 000 0 eng |
| 016 | 7 |
▼a 9918661414306676
▼2 DNLM |
| 019 | |
▼a 1391442888
▼a 1391676636
▼a 1398117071 |
| 020 | |
▼z 9780309702409 |
| 020 | |
▼z 0309702402 |
| 020 | |
▼a 0309702410 |
| 020 | |
▼a 9780309702416
▼q (electronic bk.) |
| 035 | |
▼a 3661348
▼b (N$T) |
| 035 | |
▼a (OCoLC)1400036131
▼z (OCoLC)1391442888
▼z (OCoLC)1391676636
▼z (OCoLC)1398117071 |
| 040 | |
▼a NLM
▼b eng
▼e rda
▼c NLM
▼d N$T
▼d OCLCO
▼d EBLCP
▼d YDX
▼d SMC
▼d 248032 |
| 042 | |
▼a pcc |
| 049 | |
▼a MAIN |
| 050 | 4 |
▼a QR177 |
| 060 | 00 |
▼a QW 45 |
| 082 | 04 |
▼a 616.9041 |
| 100 | 1 |
▼a Forstag, Erin Hammers,
▼e rapporteur. |
| 245 | 10 |
▼a Accelerating the development and uptake of rapid diagnostics to address antibiotic resistance :
▼b proceedings of a workshop /
▼c Erin Hammers Forstag and Carolyn Shore, rapporteurs ; Forum on Drug Discovery, Development, and Translation, Forum on Medical and Public Health Preparedness for Disasters and Emergencies, Forum on Microbial Threats, Board on Global Health, Board on Health Sciences Policy, Health and Medicine Division, National Academies of Sciences, Engineering, and Medicine. |
| 264 | 1 |
▼a Washington, DC :
▼b National Academies Press,
▼c [2023] |
| 300 | |
▼a 1 online resource (1 PDF file (xxiii, 126 pages)) :
▼b illustrations |
| 336 | |
▼a text
▼b txt
▼2 rdacontent |
| 337 | |
▼a computer
▼b c
▼2 rdamedia |
| 338 | |
▼a online resource
▼b cr
▼2 rdacarrier |
| 504 | |
▼a Includes bibliographical references. |
| 505 | 0 |
▼a Intro -- FrontMatter -- Reviewers -- Acknowledgments -- Contents -- Boxes, Figures, and Tables -- Acronyms and Abbreviations -- 1 Introduction -- 2 Exploring the Need for Rapid Diagnostics -- 3 Lessons Learned from the COVID-19 Pandemic -- 4 Incentives at the Intersection of Drug Development and Complementary Diagnostics -- 5 Health Equity Considerations -- 6 Diagnostic Stewardship -- 7 Exploring Potential Policy Options -- References -- Appendix A: Workshop Agenda -- Appendix B: Biographical Sketches of the Workshop Planning Committee and Speakers |
| 520 | 3 |
▼a The use and misuse of antibiotics contributes to the rise in drug-resistant bacteria - a serious and worsening threat to human health. The development and use of rapid point-of-care diagnostics in the healthcare setting plays an important role in avoiding unnecessary use of antimicrobials by providing clinicians with the right information at the right time to help them make decisions about appropriate drug treatment for patients. Diagnostics also have the capacity to support early detection and diagnosis of drug-resistant bacterial infections, enable disease surveillance, and help prevent disease spread. The National Academies Forum on Drug Discovery, Development, and Translation; Forum on Medical and Public Health Preparedness for Disasters and Emergencies; and Forum on Microbial Threats hosted an October 2022 workshop exploring the current landscape of rapid diagnostics to address antibiotic resistance, challenges and opportunities for spurring innovation, and practical next steps for accelerating the development of new diagnostic tools. |
| 536 | |
▼a This activity was supported by contracts between the National Academy of Sciences and Administration for Children and Families (Contract No. HHSP233201400020B; Task Order No. 75P00120F37103); American Burn Association; American College of Emergency Physicians; American College of Surgeons-Committee on Trauma; American Hospital Association; American Red Cross; American Society of Tropical Medicine and Hygiene; Amgen Inc.; Association of American Medical Colleges; Association of Public Health Laboratories; Association of State and Territorial Health Officials; AstraZeneca; Biogen; Burroughs Wellcome Fund (Contract No. 1023129, 1022390); Centers for Disease Control and Prevention (Contract No. 75D30121F00095, 75D30121D11240; Task Order No. 75D30121F00001): National Center for Emerging Zoonotic Infectious Diseases; Council of State and Territorial Epidemiologists; Critical Path Institute; East West Protection LLC; EcoHealthAlliance; Eli Lilly and Company; Emergency Nurses Association; ExxonMobil Foundation; FasterCures, Milken Institute; Foundation for the National Institutes of Health; Friends of Cancer Research; Healthcare Ready; Infectious Diseases Society of America; Johnson & Johnson (Contract No. C2022024120); Medable; Merck & Co., Inc. (Contract No. APA-21-151620; Grant No. MEM-22-160471); National Association of Chain Drug Stores; National Association of County and City Health Officials; National Association of Emergency Medical Technicians; National Fire Protection Association; National Highway Traffic Safety Administration (Contract No. 693JJ922P000037); National Institutes of Health (Contract No. HHSN263201800029I; Task Order No. HHSN26300007, HHSN26300011, HHSN26300026): National Cancer Institute, National Center for Advancing Translational Sciences, National Institute of Allergy and Infectious Diseases, National Institute of Environmental Health Sciences, National Institute of Mental Health, National Institute of Neurological Disorders and Stroke, Office of the Director; New England Journal of Medicine; New Venture Fund (Contract No. NVF-NGDF-NAT10-Subgrant-017387-2022-04-01); Office of the Assistant Secretary for Preparedness and Response (Contract No. 75A50121P00089); Sanofi (Contract No. 70602577); Takeda; The MITRE Corporation; The Rockefeller Foundation; Trauma Center Association of America; Uniformed Services University of Health Sciences (Award No. HU00012210001); U.S. Agency for International Development (Grant No. 7200AA18GR00003); U.S. Department of Defense; U.S. Department of Homeland Security (Contract No. HSHQDC-17-A-B0001; Task Order No. 70RWMD21F00000031); U.S. Department of Veterans Affairs (Contract No. 36C25022C0273); U.S. Food and Drug Administration (Contract No. 1R13FD007302-01, 75F40120P00; Award No. 5R13FD006897-03). Any opinions, findings, conclusions, or recommendations expressed in this publication do not necessarily reflect the views of any organization or agency that provided support for the project. |
| 588 | |
▼a Description based on online resource; title from PDF title page (viewed Sept. 13, 2023). |
| 590 | |
▼a OCLC control number change |
| 650 | 0 |
▼a Drug resistance
▼v Congresses. |
| 650 | 0 |
▼a Pharmaceutical technology
▼v Congresses. |
| 650 | 0 |
▼a Antibiotics
▼x Development
▼v Congresses. |
| 650 | 0 |
▼a Antibiotics
▼x Side effects
▼v Congresses. |
| 650 | 0 |
▼a COVID-19 (Disease)
▼v Congresses. |
| 650 | 0 |
▼a Drug resistance in microorganisms. |
| 650 | 12 |
▼a Drug Resistance, Bacterial |
| 650 | 22 |
▼a Rapid Diagnostic Tests |
| 650 | 6 |
▼a Bacte?ries pathoge?nes
▼x Re?sistance aux me?dicaments. |
| 650 | 6 |
▼a Re?sistance aux me?dicaments
▼v Congre?s. |
| 650 | 6 |
▼a Techniques pharmaceutiques
▼v Congre?s. |
| 650 | 6 |
▼a Antibiotiques
▼x Effets secondaires
▼v Congre?s. |
| 650 | 6 |
▼a COVID-19
▼v Congre?s. |
| 655 | 2 |
▼a Congress |
| 655 | 7 |
▼a proceedings (reports)
▼2 aat |
| 655 | 7 |
▼a Conference papers and proceedings.
▼2 lcgft |
| 655 | 7 |
▼a Actes de congre?s.
▼2 rvmgf |
| 700 | 1 |
▼a Shore, Carolyn,
▼e rapporteur. |
| 710 | 2 |
▼a National Academies of Sciences, Engineering, and Medicine (U.S.).
▼b Forum on Microbial Threats,
▼e sponsoring body. |
| 710 | 2 |
▼a National Academies of Sciences, Engineering, and Medicine (U.S.).
▼b Forum on Medical and Public Health Preparedness for Disasters and Emergencies,
▼e sponsoring body. |
| 710 | 2 |
▼a National Academies of Sciences, Engineering, and Medicine (U.S.).
▼b Forum on Drug Discovery, Development, and Translation,
▼e sponsoring body. |
| 711 | 2 |
▼a Accelerating the Development and Uptake of Rapid Diagnostics to Address Antibiotic Resistance (Workshop)
▼d (2022 :
▼c Washington, D.C.) |
| 776 | 08 |
▼i Print version:
▼a National Academies of Sciences, Engineering, and Medicine
▼t Accelerating the Development and Uptake of Rapid Diagnostics to Address Antibiotic Resistance
▼d Washington, D.C. : National Academies Press,c2024
▼z 9780309702409 |
| 856 | 40 |
▼3 EBSCOhost
▼u https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=3661348 |
| 938 | |
▼a EBSCOhost
▼b EBSC
▼n 3661348 |
| 990 | |
▼a 관리자 |
| 994 | |
▼a 92
▼b N$T |